Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
-
Wawrinka falls in first round of Monte Carlo Masters
-
Ex-England rugby international Lawes to leave Brive
-
Fit-again Mbappe at Real Madrid for clashes like Bayern tie: Arbeloa
-
Swimmers McKeown, O'Callaghan and Chalmers dominate at Australian Open
-
Bucha: When the Russian killers came...
-
Iran, a Terrorist State with No Right to Exist
-
African players in Europe: Semenyo scores as City rout Liverpool
-
Israeli strikes kill Iran Guards intel chief as Trump deadline looms
-
Saving energy in everyday life or a complete rip-off?
-
US sprint star Richardson wins Australia's Stawell Gift in record time
-
Rockets down Warriors in Curry return, Flagg carries Mavs past Lakers
-
Artemis mission approaches lunar loop for first flyby since 1972
-
Israeli rescuers search for missing in building strike, two dead
-
Defiant Iran ramps up attacks after Trump warning
-
Saudi oasis town adjusts to life in the firing line
-
Pogacar stays humble with Monument history beckoning
-
Real Madrid hoping Champions League magic halts Bayern juggernaut
-
Sputtering Arsenal face test of character in Sporting clash
-
'Not the Cairo we know': Energy shock from Iran war dims Egypt nights
-
Tokyo, Seoul shares gain, war sends oil higher
-
Artemis mission headed for first lunar flyby since 1972
-
South Korea president says regrets 'reckless' drones sent to North
-
Coughlin captures third LPGA title at Aramco Championship
-
What to know about the Artemis 2 mission's Moon flyby
-
Mystique of the green jacket endures as Masters looms
-
In El Salvador's mass trials, 'the innocent pay for the guilty'
-
Trump makes stark threat to Iran after US airman rescued
-
MyPlanAdvocate Rebrands as MPA and Integrates HealthyLabs, Bringing AI-Powered Performance Marketing In-House
-
XCF Global and Axens North America Announce Commercial Collaboration for Vegan(R) Technology
-
SMX Launches Digital Material Passport Platform (DMPP) Enabling Verified Material Identity, Traceability and Real-World Asset Tokenization
-
TrustNFT Releases White Paper on Corporate Costs of Email Impersonation, Documenting $2.9 Billion in Annual Losses and Growing Brand Liability Risk
-
Commonwealth Wholesale Corporation Signs Lease at Central Port Logistics Center Building 4 Strategically Located Near the Port of Savannah
-
Datavault AI CEO Nathaniel T. Bradley to Deliver Flagship Keynotes on Breakthrough RWA Tokenization at CONV3RGENCE London and AssetRush × Zurich 2026
-
HarrisQuest Launches Lou, a Voice-Enabled AI Analyst Built Inside The Harris Poll's Brand Tracking Platform
-
Fortitude Gold Declares April 2026 Monthly Dividend
-
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
-
Arrive AI Secures Tenth U.S. Patent, Positioning as the Critical Infrastructure Layer for Autonomous Delivery at Scale
-
National Study of 2,300+ Women Finds Social Connection Shapes Volunteer Experience Amid Competing Work, Caregiving, and Life Demands
-
Prof. Abdul Al Lily Announces the Release of The Naughty AI CEO, Exploring the Future of AI-Driven Leadership
-
Hillcrest Closes Shares for Debt Offering
-
Elektros Positions Itself at the Center of High-Stakes EV Infrastructure Opportunity Through Strategic Engagement with Major Global Automotive Leader
-
ReElement Technologies Announces April Conference and Event Schedule
-
Greenpro Capital Corp. Successfully Acquires Stake in AI Forekast Limited, an Augmented Intelligence Provider
-
Ondas' 4M Defense Wins Competitive Tender for Large-Scale Border Demining Program with Opportunity Expected to Exceed $50 Million
-
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
-
MDCE's Snapshot Recipes App Scales Marketing Strategy Beyond Initial Podcast Deals with Expanded iHeart Campaign
-
SMX Announces Launch of Its Digital Material Passport Platform, Enabling Real-World Asset Tokenisation and Global Material Traceability
-
Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness
-
Avino Announces Normal Course Issuer Bid for Common Shares
-
Revolve Signs Interconnection Agreement for 130 MW EL 24 Wind Project in Mexico
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.
2025 Highlights
Revenue of $36.3 million, representing a 4.1% increase compared to 2024.
$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.
Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.
Advancement of proprietary antiviral research, including a new series of orally active, non‑covalent PLpro protease inhibitors that demonstrated dose‑dependent antiviral activity in SARS‑CoV‑2‑infected mice, strong potency in cellular models, and favorable pharmacokinetics.
Management Commentary
"We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO. "Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life‑saving medicines to the market."
Financial Summary (in millions)
2025 | 2024 | |
|---|---|---|
Revenue | $36.31 | $34.87 |
Gross Profit | $12.26 | $10.67 |
General & Administrative Expenses | $18.48 | $16.48 |
Net Loss | $5.98 | $5.13 |
The increase in General & Administrative Expenses in 2025 was primarily driven by a non‑cash, non‑recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company's operating performance reflects a meaningful improvement over 2024.
In January 2026, Sunshine Biopharma implemented cost‑reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company's focus on achieving near‑term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.
About Sunshine Biopharma
Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:
K1.1 mRNA, an mRNA‑Lipid Nanoparticle therapeutic candidate targeting liver cancer.
PLpro protease inhibitor, a small‑molecule antiviral candidate for SARS‑related coronavirus infections.
Additional information is available at www.sunshinebiopharma.com.
Forward‑Looking Statements
This press release contains forward‑looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company's financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company's most recent SEC filings for additional information.
Contact:
Camille Sebaaly, CFO
Direct Line: 514‑814‑0464
[email protected]
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
Y.Kobayashi--AMWN